ZHENG Zi-hui, ZHANG Bi-hua, LI Qiong, WANG Yang, ZHANG Bai-ge, MA Lin, LI Wen-ying, JIN Peng-fei
Objective To systematically evaluate the efficacy and safety of Compound Glycyrrhizin with Levocetirizine in the chronic urticaria（CU）. Methods PubMed， Cochrane Library，Embase， CNKI and Wanfang databases were searched from the establishment of the database to January 31， 2022. Randomized controlled trials （RCTs） of Compound Glycyrrhizin combined with Levocetirizine in the treatment of CU published in Chinese journals were collected in the Chinese database， and journals were not in the English database. Two researchers extracted data， selected literatures， and evaluated the risk of bias in the included articles. Meta-analysis was performed using RevMan 5.4. Results A total of 8 RCTs were included in the analysis， involving 918 patients， 474 in the experimental group and 444 in the control group. Results of the Meta-analysis showed that the total effective rate in the CU（OR=6.14，95%CI：4.10 to 9.20， P<0.01）， cure rate （OR=2.75，95%CI：2.04 to 3.72， P<0.01），marked effective rate（OR=1.58，95%CI：1.13 to 2.22， P<0.01），recurrence rate（OR=0.24， 95%CI：0.11 to 0.52， P<0.01），total symptom score （TSS） （SMD＝-2.17，95%CI：-3.76 to -0.59，P<0.01） and dermatology life quality index（DLQI）（MD＝-1.92，95%CI：-3.76 to -0.09，P<0.05） of the observation group were significantly better than the control group . In terms of adverse reactions， the observation group （OR＝0.56，95%CI：0.35 to 0.90，P<0.05） was significantly lower than the control group. Conclusion The existing evidences suggest that Compound Glycyrrhizin with Levocetirizine is safer and more effective in the treatment of CU， compared to Levocetirizine alone. It is limited due to the quantity and quality of the included studies， and the above conclusions need to be verified by more high-quality RCTs.
